Kendall Capital Management Amgen Inc Transaction History

Kendall Capital Management

$316 Million
Q3 2024

A detailed history of Kendall Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Kendall Capital Management holds 3,940 shares of AMGN stock, worth $1.12 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

3,940

Previous 4,110 4.14%

Holding current value

$1.12 Million

Previous $1.28 Million 1.17%

% of portfolio

0.4%

Previous 0.44%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$309.38 - $337.38 $52,594 - $57,354	-170 Reduced 4.14%	3,940 $1.27 Million
Q2 2024 Aug 12, 2024	SELL	$262.75 - $319.31 $109,304 - $132,832	-416 Reduced 9.19%	4,110 $1.28 Million
Q1 2024 May 10, 2024	SELL	$268.87 - $324.56 $25,542 - $30,833	-95 Reduced 2.06%	4,526 $1.29 Million
Q4 2023 Jan 26, 2024	SELL	$255.7 - $288.46 $43,469 - $49,038	-170 Reduced 3.55%	4,621 $1.33 Million
Q3 2023 Oct 31, 2023	SELL	$218.65 - $271.46 $6,559 - $8,143	-30 Reduced 0.62%	4,791 $1.29 Million
Q2 2023 Jul 28, 2023	BUY	$214.27 - $253.37 $74,994 - $88,679	350 Added 7.83%	4,821 $1.07 Million
Q1 2023 May 11, 2023	SELL	$225.79 - $275.2 $7,451 - $9,081	-33 Reduced 0.73%	4,471 $1.08 Million
Q4 2022 Jan 30, 2023	SELL	$229.03 - $291.01 $13,741 - $17,460	-60 Reduced 1.31%	4,504 $1.18 Million
Q3 2022 Nov 02, 2022	SELL	$224.46 - $253.15 $5,611 - $6,328	-25 Reduced 0.54%	4,564 $1.03 Million
Q2 2022 Jul 29, 2022	SELL	$230.71 - $256.74 $17,303 - $19,255	-75 Reduced 1.61%	4,589 $1.12 Million
Q1 2022 May 06, 2022	BUY	$219.27 - $242.57 $30,697 - $33,959	140 Added 3.09%	4,664 $1.13 Million
Q3 2021 Nov 05, 2021	BUY	$212.27 - $248.7 $1,910 - $2,238	9 Added 0.2%	4,524 $962,000
Q2 2021 Jul 30, 2021	BUY	$233.58 - $259.14 $44,380 - $49,236	190 Added 4.39%	4,515 $1.1 Million
Q4 2020 Feb 08, 2021	SELL	$216.38 - $257.67 $36,784 - $43,803	-170 Reduced 3.78%	4,325 $994,000
Q3 2020 Oct 22, 2020	SELL	$234.65 - $260.95 $275,713 - $306,616	-1,175 Reduced 20.72%	4,495 $1.14 Million
Q2 2020 Jul 30, 2020	SELL	$197.81 - $242.74 $71,805 - $88,114	-363 Reduced 6.02%	5,670 $1.34 Million
Q1 2020 Apr 27, 2020	SELL	$182.24 - $241.7 $246,935 - $327,503	-1,355 Reduced 18.34%	6,033 $1.22 Million
Q4 2019 Jan 24, 2020	BUY	$189.21 - $243.2 $10,406 - $13,376	55 Added 0.75%	7,388 $1.78 Million
Q3 2019 Nov 12, 2019	SELL	$174.11 - $208.62 $35,692 - $42,767	-205 Reduced 2.72%	7,333 $1.42 Million
Q2 2019 Aug 09, 2019	SELL	$166.7 - $195.41 $32,506 - $38,104	-195 Reduced 2.52%	7,538 $1.39 Million
Q1 2019 May 08, 2019	SELL	$180.87 - $203.88 $16,278 - $18,349	-90 Reduced 1.15%	7,733 $1.47 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $39,248 - $45,815	220 Added 2.89%	7,823 $1.52 Million
Q3 2018 Oct 29, 2018	SELL	$185.29 - $208.89 $25,940 - $29,244	-140 Reduced 1.81%	7,603 $1.58 Million
Q2 2018 Jul 27, 2018	SELL	$166.05 - $186.51 $4,317 - $4,849	-26 Reduced 0.33%	7,743 $1.43 Million
Q1 2018 May 14, 2018	BUY	$169.43 - $198.0 $10,165 - $11,880	60 Added 0.78%	7,769 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $1.3 Million - $1.45 Million	7,709	7,709 $1.34 Million

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $152B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kendall Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Kendall Capital Management with notifications on news.

Account

Kendall Capital Management Amgen Inc Transaction History